Vistagen announces strategic partnership with everinsight therapeutics for up to $177 million

Vistagen therapeutics reports fiscal year 2020 results and provides cns pipeline update.vistagen therapeutics inc - announces strategic partnership with everinsight therapeutics for up to $177 million in upfront & potential milestone payments.vistagen therapeutics inc - developing three differentiated, patent-protected, cns product candidates.vistagen therapeutics inc - co & everinsight therapeutics entered into partnership for phase 3 clinical development & commercialization of ph94b.vistagen therapeutics inc - at march 31, 2020, vistagen had cash and cash equivalents of $1.4 million.
VTGN Ratings Summary
VTGN Quant Ranking